The CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease

Laura A. Bosmans, Lena Bosch, Pascal J.H. Kusters, Esther Lutgens, Tom T.P. Seijkens

Research output: Contribution to journalReview articlepeer-review


Chronic inflammation drives the development of atherosclerosis. Despite optimal treatment of classical cardiovascular risk factors, a substantial portion of the population has elevated inflammatory biomarkers and develops atherosclerosis-related complications, indicating that a residual inflammatory risk drives atherosclerotic cardiovascular disease in these patients. Additional anti-inflammatory therapeutic strategies are therefore required. The co-stimulatory molecule CD40 and its ligand CD40L (CD154) have a central role in the regulation of the inflammatory response during the development of atherosclerosis by modulating the interaction between immune cells and between immune cells and non-immune cells. In this review, we discuss the role of the CD40-CD40L dyad in atherosclerosis, and we discuss recent studies on the therapeutic potential of novel CD40-CD40L targeting strategies in cardiovascular medicine.

Original languageEnglish (US)
Pages (from-to)13-22
Number of pages10
JournalJournal of cardiovascular translational research
Issue number1
StatePublished - Feb 2021


  • Atherosclerosis
  • CD40
  • CD40L
  • Cardiovascular disease
  • Immune checkpoint proteins
  • Inflammation

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmaceutical Science
  • Cardiology and Cardiovascular Medicine
  • Genetics(clinical)


Dive into the research topics of 'The CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease'. Together they form a unique fingerprint.

Cite this